News

News 30.01.2020 Schlieren (Zurich), Switzerland, January 30, 2020 – Kuros Biosciences (SIX: KURN) today announced the publication of data from a clinically-relevant preclinical model comparing MagnetOs with autologous bone, Vitoss® BA2X (Stryker Corp.) and Novabone Putty® (Novabone Products, LLC) in instrumented posterolateral spinal fusion in sheep. Utilizing multiple assessments for fusion, the study...

News 10.01.2020 Zurich-Schlieren, Switzerland, January 10, 2020. Proteomedix, a swiss diagnostics company committed to advance prostate cancer care announced today that its board of directors has appointed Helge Lubenow as Chief Executive Officer effective January 1, 2020. Helge will succeed Ralph Schiess, co-founder of Proteomedix who is transitioning to a newly established...

News 27.12.2019 Zurich-Schlieren, Switzerland, December 27, 2019. Molecular Partners AG (SIX:MOLN), a clinicalstage biotech company pioneering the use of DARPin® therapeutics to treat serious diseases, announces the receipt of Orphan Drug Designation by the US Food and Drug Administration (FDA) for its novel therapeutic, MP0250, for the treatment of Multiple Myeloma. MP0250 is...

News 07.12.2019 Zurich-Schlieren, Switzerland, December 7, 2019. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics to treat serious diseases, today announced a poster presentation at the American Society of Hematology 61st Annual Meeting in Orlando, FL, highlighting the activity of its tri-specific DARPin® drug candidate, MP0250, in patients undergoing...

News 04.12.2019 Schlieren (Zurich), Switzerland, December 3, 2019 – Kuros Biosciences (SIX: KURN) (the Company or Kuros) announces the final number of Offered Shares and gross proceeds from the Rights Offering and Share Offering, first announced on November 19, 2019, in which a total of up to 6,405,022 new registered shares of...